Report LibraryAll Reports
Datamonitor Healthcare CNS Disease Analysis: Epilepsy
January 08, 2020The breadth of each epilepsy drug’s product label is highly pertinent to its competitive edge and provides impetus for the ongoing uptake of branded anti-epileptics. Even in the saturated partial-onset seizures (POS) market, numerous label expansions broadening POS drug usage to monotherapy use and the treatment of pediatric patients are likely to bolster uptake. Further expansion to generalized and secondary generalized seizures, specific subpopulations such as refractory epilepsy patients, and rare pediatric epilepsy patients may also help to maximize commercial potential.
This Datamonitor Healthcare report contains a Disease Analysis module.
Dravet Syndrome (Epilepsy)
Infantile Spasms (West Syndrome; Epilepsy)
Lennox-Gastaut Syndrome (LGS; Epilepsy)
Partial Seizures (Epilepsy)
Seizure Disorders (Epilepsy)